title: Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients.
abstract: Alzheimer's disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients' genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with poor response to the drug. In a sample of 415 AD cases, we found evidence of association between rs1080985 and response to donepezil after 6 months of therapy (OR [95% CI]: 1.74 [1.01-3.00], p = 0.04). Rs1080985 might be useful as predictor of poor response to short-term donepezil treatment.
authors.affiliation: Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy. diego.albani@marionegri.it
authors.forename: Diego
authors.initials: D
authors.lastname: Albani
authors.forename: Filippo
authors.initials: F
authors.lastname: Martinelli Boneschi
authors.forename: Gloria
authors.initials: G
authors.lastname: Biella
authors.forename: Giacomo
authors.initials: G
authors.lastname: Giacalone
authors.forename: Sara
authors.initials: S
authors.lastname: Lupoli
authors.forename: Francesca
authors.initials: F
authors.lastname: Clerici
authors.forename: Luisa
authors.initials: L
authors.lastname: Benussi
authors.forename: Roberta
authors.initials: R
authors.lastname: Ghidoni
authors.forename: Daniela
authors.initials: D
authors.lastname: Galimberti
authors.forename: Rosanna
authors.initials: R
authors.lastname: Squitti
authors.forename: Stefania
authors.initials: S
authors.lastname: Mariani
authors.forename: Annamaria
authors.initials: A
authors.lastname: Confaloni
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Bruno
authors.forename: Claudio
authors.initials: C
authors.lastname: Mariani
authors.forename: Elio
authors.initials: E
authors.lastname: Scarpini
authors.forename: Giuliano
authors.initials: G
authors.lastname: Binetti
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Magnani
authors.forename: Massimo
authors.initials: M
authors.lastname: Franceschi
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Forloni
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D004261:DNA Replication / Q000187:drug effects / Q000235:genetics*; D000077265:Donepezil; D005260:Female; D005500:Follow-Up Studies; D005819:Genetic Markers / Q000187:drug effects / Q000235:genetics; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D010880:Piperidines / Q000627:therapeutic use*; D011110:Polymorphism, Genetic / Q000187:drug effects / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D005819:Genetic Markers; D007189:Indans; D010880:Piperidines; D000077265:Donepezil; D019389:Cytochrome P-450 CYP2D6